A5002858329- Complement system in diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Iron Metabolism and Disorders
- Renal Diseases and Glomerulopathies
- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Erythropoietin and Anemia Treatment
- Salmonella and Campylobacter epidemiology
- Family and Patient Care in Intensive Care Units
- Silicon Carbide Semiconductor Technologies
- Legionella and Acanthamoeba research
- Trace Elements in Health
- Medical Case Reports and Studies
- Infective Endocarditis Diagnosis and Management
- Liver Disease and Transplantation
- Vascular Tumors and Angiosarcomas
- Heparin-Induced Thrombocytopenia and Thrombosis
- Gallbladder and Bile Duct Disorders
- Vascular anomalies and interventions
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Vitamin C and Antioxidants Research
- Vibrio bacteria research studies
Baylor College of Medicine
2023-2025
The Ohio State University
2020-2022
The Ohio State University Wexner Medical Center
2020
Southwestern Medical Center
2019
The University of Texas Southwestern Medical Center
2018-2019
Wythenshawe Hospital
2006
University of Manchester
2006
Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors experience high rates of adverse health sequelae and increased mortality over long-term follow-up. We conducted this multicenter cohort study to evaluate causes death in iTTP survivors. Between 2003 2020, 222 patients were enrolled the Ohio State University Johns Hopkins TTP registries followed for a median 4.5 (interquartile range [IQR], 75 0.4-11.5) years. Nine died during their first episode, 29 Mortality rate...
Background/Objectives: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, chronically relapsing disorder that causes life-threatening microangiopathy. Many survivors in clinical remission show evidence of ongoing silent cerebral infarction and neurocognitive deficits. Prospective longitudinal studies this population are needed to acquire complete understanding the mechanism behind neurologic injury. We aimed assess feasibility multicenter prospective study neuropsychological...
De novo and relapsed immune-mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to occurred following severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccination. Here, we present a case of 28-year-old woman who received the tozinameran (BNT162b2, Pfizer-BioNtech) vaccine for COVID-19 experienced an iTTP relapse during longitudinal follow-up. She 30 months after her initial diagnosis, while she was in clinical remission. not complete ADAMTS-13 remission, as...
Cardiovascular disease is a leading cause of death in survivors immune-mediated thrombotic thrombocytopenic purpura (iTTP), but the epidemiology major adverse cardiovascular events (MACE) iTTP unknown. We evaluated prevalence and risk factors for MACE, defined as composite non-fatal or fatal myocardial infarction (MI), stroke, cardiac revascularization, during clinical remission two large cohorts (Johns Hopkins University Ohio State University). Of 181 patients followed ≥ 3 months after...
We present a case of Vibrio vulnificus septic shock and cellulitis in patient with chronic liver disease that occurred after obtaining leg tattoo subsequent seawater exposure the Gulf Mexico. Initial suspicion for V. was high he started on empiric doxycycline ceftriaxone at admission. Blood wound cultures grew oxidase positive comma-shaped Gram-negative rods ultimately confirmed to be vulnificus. Despite aggressive initial treatment, developed died. This highlights association mortality...
Thrombotic microangiopathies (TMAs) represent a heterogeneous group of entities characterized by the same phenotype: microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. Over last decades, two major syndromes with distinct pathophysiology have been recognized: thrombotic thrombocytopenic purpura (TTP) uremic syndrome (HUS). A severe deficiency ADAMTS13 (A Disintegrin And Metalloproteinase ThromboSpondin type 1 motifs, member 13) enzyme has established as key feature for...